Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study-Reference-Cited by-同舟云学术

Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study

Published:2019-05 Issue:5 Volume:19 Page:285-289
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Goldsmith Scott R.^ORCID,Fiala Mark A.,Dukeman James,Ghobadi Armin^ORCID,Stockerl-Goldstein Keith,Schroeder Mark A.,Tomasson Michael^ORCID,Wildes Tanya M.,Vij Ravi

Funder

Janssen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference21 articles.

1. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma;Kastritis;Haematologica,2017

2. Comprehensive evaluation of the Revised International Staging System in multiple myeloma patients treated with novel agents as a primary therapy;Cho;Am J Hematol,2017

3. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma;Tandon;Blood Cancer J,2017

4. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group;Palumbo;J Clin Oncol,2015

5. Is the Revised International Staging System for myeloma valid in a real world population?;Walker;Br J Haematol,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omic and functional screening reveal targetable vulnerabilities inTP53mutated multiple myeloma;2024-08-23

2. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07

3. Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer;AAPS PharmSciTech;2024-03-06

4. Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma;2024-03-05

5. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma;Frontiers in Immunology;2023-11-15